乌鸦传媒

In trials, guselkumab more than doubled remission rates versus placebo

PREDICT-UC trial found no benefit with intensified or accelerated regimens

Infusion services and other therapies must be delivered without delay

Also in TTHealthWatch: a monoclonal antibody for ulcerative colitis

Pricing, payer policies keep market leader on top

Dual-acting IL-23 inhibitor tops placebo, ustekinumab in phase III trials

Female patients appeared to derive the greatest benefit, researchers say

Agency finds risk for intrahepatic cholestasis of pregnancy mostly in IBD, lupus patients

Study identified factors and strategies for maintaining response

Observational VA data support recommendations for monitoring with initiation

Studies may explain some cases of rare opportunistic infections

A significant issue for DMARD and steroid users in the American Southwest

The IL-23 inhibitor led to more clinical remissions vs the IL-12/23 inhibitor